Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis.

Sher, Amna Falak; Wu, Shucai

doi:10.1200/jco.2010.28.15_suppl.9136

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous meta-analysis of bevacizumab RCTs is in agreement with our results, showing a risk-lowering effect of bevacizumab on anemia adverse events [5,91,92]. The only monoclonal antibody that seemed to increase the risk for anemia was trastuzumab (RR, 1.23).…”

Section: Discussionsupporting

confidence: 92%

The Risk for Anemia with Targeted Therapies for Solid Tumors

et al. 2012

View full text Add to dashboard Cite

Background. Anemia is a common manifestation in patients with cancer. Little is known about the frequency of and risk for anemia with targeted therapies used to treat solid tumors.Methods. We performed a meta-analysis of randomized controlled trials of solid tumors by comparing targeted therapy (alone or in combination) with standard therapy alone to calculate the incidence and relative risk (RR) for anemia events associated with these agents. Overall, 24,310 patients were included in the analysis.Results. The addition of targeted therapies to standard treatment (chemotherapy or placebo/best supportive care) increased the risk for all grades of anemia by 7%. The RR for all grades (incidence, 44%) and grades 1-2 (incidence, 38.9%) of anemia was higher with biological therapies

show abstract

Section: Discussionsupporting

confidence: 92%

The Risk for Anemia with Targeted Therapies for Solid Tumors

et al. 2012

View full text Add to dashboard Cite

show abstract

“…One such example has been reported in a metaanalytical study involving solid tumour patients exposed to appropriate chemotherapeutics alone and in combination with a humanised monoclonal antibody (bevacizumab), with bevacizumab able to significantly reduce both incidence and risk rates of anaemia in a dose-dependent manner, as compared to chemotherapy alone. 154 However, with chemotherapy-related anaemia being a frequent symptom in cancer patients and lack of extensive research on the pathogenetic mechanisms of anaemia development as a response to chemotherapeutics, information on antianaemic therapies remains limited. 104 Particularly, chemotherapy-induced lower grade anaemia appears to be more frequent than higher grade anaemia, usually requiring a blood transfusion.…”

Section: Metabolism For Cancer Therapymentioning

confidence: 99%

“…For instance, if AID has been identified as a potential cause for iron deficiency in a cancer patient, a favourable therapy regimen must include newer or combination therapeutics maintaining lower anaemia incidence and risk rates. One such example has been reported in a meta‐analytical study involving solid tumour patients exposed to appropriate chemotherapeutics alone and in combination with a humanised monoclonal antibody (bevacizumab), with bevacizumab able to significantly reduce both incidence and risk rates of anaemia in a dose‐dependent manner, as compared to chemotherapy alone 154 . However, with chemotherapy‐related anaemia being a frequent symptom in cancer patients and lack of extensive research on the pathogenetic mechanisms of anaemia development as a response to chemotherapeutics, information on antianaemic therapies remains limited 104 .…”

Section: Targeting Iron Metabolism For Cancer Therapymentioning

confidence: 99%

Iron imbalance in cancer: Intersection of deficiency and overload

Basak

Kanwar

2022

Cancer Medicine

View full text Add to dashboard Cite

Iron, an essential trace element, plays a complex role in tumour biology. While iron causes cancer clearance through toxic free radical generation, iron‐induced free radical flux also acts as a cancer promoter. These fates majorly guided through cellular response towards pro‐oxidant and antioxidant settings in a tumour microenvironment, designate iron‐induced oxidative stress as a common yet paradoxical factor in pro‐tumorigenesis as well as anti‐tumorigenesis, posing a challenge to laying down iron thresholds favouring tumour clearance. Additionally, complexity of iron's association with carcinogenesis has been extended to iron‐induced ROS's involvement in states of both iron deficiency and overload, conditions identified as comparable, inevitable and significant coexisting contributors as well as outcomes in chronic infections and tumorigenesis. Besides, iron overload may also develop as an unwanted outcome in certain cancer patients, as a result of symptomatic anaemia treatment owed to irrational iron‐restoration therapies without a prior knowledge of body's iron status with both conditions synergistically acting towards tumour aggravation. The co‐play of iron deficiency and overload along with iron's pro‐tumour and antitumour roles with intersecting mechanisms, thus presents an unpredictable regulatory response loop in a state of malignancy. The relevance of iron's thresholds beyond which it proves to be beneficial against tumorigenesis hence becomes questionable. These factors pose a challenge, over establishing if iron chelation or iron flooding acts as a better approach towards antitumour therapies. This review presents a critical picture of multiple contrasting features of iron's behaviour in cancer, leading towards two conditions lying at opposite ends of a spectrum: iron deficiency and overload in chronic disease conditions including cancer, hence, validating the critical significance of diagnosis of patients' iron status prior to opting for subsequent therapies.

show abstract

Bone Marrow Toxicity: Red Blood Cells

Gascón¹

2012

Side Effects of Medical Cancer Therapy

View full text Add to dashboard Cite

Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis.

Cited by 3 publications

References 0 publications

The Risk for Anemia with Targeted Therapies for Solid Tumors

The Risk for Anemia with Targeted Therapies for Solid Tumors

Iron imbalance in cancer: Intersection of deficiency and overload

Bone Marrow Toxicity: Red Blood Cells

Contact Info

Product

Resources

About